The changing therapeutic landscape of castration-resistant prostate cancer - PubMed (original) (raw)

Review

The changing therapeutic landscape of castration-resistant prostate cancer

Timothy A Yap et al. Nat Rev Clin Oncol. 2011.

Abstract

Castration-resistant prostate cancer (CRPC) has a poor prognosis and remains a significant therapeutic challenge. Before 2010, only docetaxel-based chemotherapy improved survival in patients with CRPC compared with mitoxantrone. Our improved understanding of the underlying biology of CRPC has heralded a new era in molecular anticancer drug development, with a myriad of novel anticancer drugs for CRPC entering the clinic. These include the novel taxane cabazitaxel, the vaccine sipuleucel-T, the CYP17 inhibitor abiraterone, the novel androgen-receptor antagonist MDV-3100 and the radioisotope alpharadin. With these developments, the management of patients with CRPC is changing. In this Review, we discuss these promising therapies along with other novel agents that are demonstrating early signs of activity in CRPC. We propose a treatment pathway for patients with CRPC and consider strategies to optimize the use of these agents, including the incorporation of predictive and intermediate end point biomarkers, such as circulating tumor cells.

PubMed Disclaimer

Similar articles

• Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.
  Altavilla A, Iacovelli R, Procopio G, Alesini D, Risi E, Campennì GM, Palazzo A, Cortesi E. Altavilla A, et al. Cancer Biol Ther. 2012 Sep;13(11):1001-8. doi: 10.4161/cbt.21188. Epub 2012 Jul 24. Cancer Biol Ther. 2012. PMID: 22825325 Free PMC article. Review.
• Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?
  Yap TA, Swanton C, de Bono JS. Yap TA, et al. EPMA J. 2012 Jan 12;3(1):3. doi: 10.1007/s13167-011-0138-2. EPMA J. 2012. PMID: 22738151 Free PMC article.
• Management of patients with castration-resistant disease.
  Pezaro C, Omlin A, Lorente D, de Bono J. Pezaro C, et al. Hematol Oncol Clin North Am. 2013 Dec;27(6):1243-60, ix. doi: 10.1016/j.hoc.2013.08.008. Epub 2013 Sep 20. Hematol Oncol Clin North Am. 2013. PMID: 24188261 Review.
• [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
  Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. Mottet N, et al. Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Actas Urol Esp. 2011. PMID: 21757258 Spanish.
• Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
  Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Crawford ED, et al. J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. J Urol. 2015. PMID: 26196735 Review.

Cited by

• Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naïve Prostate Cancer in Japanese Men.
  Nakagawa R, Iwamoto H, Makino T, Naito R, Kadomoto S, Akatani N, Yaegashi H, Kawaguchi S, Nohara T, Shigehara K, Izumi K, Kadono Y, Takamatsu A, Yoshida K, Mizokami A. Nakagawa R, et al. Cancers (Basel). 2022 Oct 2;14(19):4822. doi: 10.3390/cancers14194822. Cancers (Basel). 2022. PMID: 36230745 Free PMC article.
• Androgen receptors beyond prostate cancer: an old marker as a new target.
  Munoz J, Wheler JJ, Kurzrock R. Munoz J, et al. Oncotarget. 2015 Jan 20;6(2):592-603. doi: 10.18632/oncotarget.2831. Oncotarget. 2015. PMID: 25595907 Free PMC article. Review.
• Pre-Exposure to Stress-Inducing Agents Increase the Anticancer Efficacy of Focused Ultrasound against Aggressive Prostate Cancer Cells.
  Murad HY, Chandra PK, Kelly CA, Khurana N, Yu H, Bortz EP, Hong SN, Mondal D, Khismatullin DB. Murad HY, et al. Antioxidants (Basel). 2022 Feb 9;11(2):341. doi: 10.3390/antiox11020341. Antioxidants (Basel). 2022. PMID: 35204223 Free PMC article.
• Molecular imaging of urogenital diseases.
  Cho SY, Szabo Z. Cho SY, et al. Semin Nucl Med. 2014 Mar;44(2):93-109. doi: 10.1053/j.semnuclmed.2013.10.008. Semin Nucl Med. 2014. PMID: 24484747 Free PMC article. Review.
• Targeted α-particle therapy of bone metastases in prostate cancer.
  Jadvar H, Quinn DI. Jadvar H, et al. Clin Nucl Med. 2013 Dec;38(12):966-71. doi: 10.1097/RLU.0000000000000290. Clin Nucl Med. 2013. PMID: 24212441 Free PMC article. Review.

References

1. 1. Curr Cancer Drug Targets. 2010 Jun;10(4):392-401 - PubMed
2. 1. Nat Rev Urol. 2011 May 17;8(6):301-11 - PubMed
3. 1. Clin Cancer Res. 2008 Oct 1;14(19):6302-9 - PubMed
4. 1. J Clin Oncol. 2008 Jan 10;26(2):242-5 - PubMed
5. 1. Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):656-60 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information